CONTINUOUS PAT FOR DOWNSTREAM MANUFACTURING

Posted on November 8, 2024

***Paul Gillham**, Innovations Director, Optimal Industrial Technologies*

In the complex and highly regulated world of pharmaceutical manufacturing, quality and efficiency are paramount. This is especially true when it comes to downstream processes, in production.

The nature of downstream manufacturing means that it is resource-intensive and fraught with challenges that can impact both the cost and quality of the final product. This is reflected in the fact that downstream processing alone can account for 50-80% of the total manufacturing costs in biopharmaceutical production[1].

These high costs are driven by the need for extensive purification stages and the complexity of formulation to maintain product stability and efficacy. On top of that, this complexity and expense is compounded by the variability in raw material quality and process conditions, which can lead to inconsistencies in product quality and yield if not properly managed.

To remain competitive, manufacturers must find ways to reduce these costs while maintaining the highest standards of product quality. One of the most effective methods to achieve this is by implementing continuous Process Analytical Technology (PAT).

A Focus on Downstream

Downstream pharmaceutical manufacturing faces several unique challenges and needs in its pursuit of stability and controlled product quality—particularly when compared to upstream manufacturing. While upstream processes can focus on maintaining optimal conditions for growth and viability, downstream processes are tasked with achieving stable and controlled product quality during production.

Downstream processing in pharmaceutical manufacturing faces several significant challenges. These include unstable inlet streams, where variations in the quality and composition of raw materials can lead to inconsistencies in the final product. Additionally, downstream processes often involve complex unit operations, such as chromatography, filtration, and drying, each of which requires precise control to ensure product quality. These processes are not only technically demanding but also resource-intensive, further complicating the maintenance of consistent quality and efficiency.

Unstable inlet streams can cause fluctuations that affect the efficiency of purification and other downstream processes. For instance, variations in the concentration of impurities or active pharmaceutical ingredients (APIs) can disrupt the delicate balance required for optimal purification, leading to potential product losses or the need for extensive reprocessing.

The complexity of unit operations in downstream processing also presents a formidable challenge. Each step, from separation and purification to formulation and packaging, must be meticulously controlled to maintain the integrity and efficacy of the pharmaceutical product. These operations often involve sophisticated monitoring equipment and techniques, such as high-performance liquid chromatography (HPLC), tangential flow filtration (TFF), and lyophilisation.

Managing these operations requires advanced technological solutions that can provide real-time feedback and precise adjustments to maintain optimal conditions. In other words, it needs continuous PAT.

What is Continuous PAT?

PAT is a framework designed to analyse and control pharmaceutical manufacturing processes. It aims to ensure product quality by measuring and controlling Critical Process Parameters (CPP) and Critical Quality Attributes (CQA).

By monitoring these parameters, PAT helps manufacturers maintain the desired conditions throughout the production process, ensuring that each product batch meets stringent quality standards. PAT tools can include a variety of analytical techniques, such as spectroscopy, chromatography, and other sensor-based technologies that provide real-time data on the manufacturing process.

When it comes to continuous PAT, the focus shifts towards integrating these analytical tools directly into a continuous manufacturing process. This approach differs from traditional batch processing by maintaining an uninterrupted flow of production, which allows for effective real-time monitoring and control.

Continuous PAT enables the immediate detection and correction of any deviations from the desired process conditions, and monitors trending towards those deviations. This ensures that the manufacturing process remains within specified limits at all times. The resulting real-time feedback loop is critical for maintaining consistent product quality and reducing variability.



As the pharmaceutical industry continues to evolve, the adoption of continuous PAT will be essential for maintaining a compe
edge and meeting rising quality and efficiency demands. (iStock-1465061566)

How Continuous PAT Benefits Downstream Manufacturing

• *Enhanced purification efficiency*

Continuous PAT technologies like real-time HPLC, FTIR, and Raman spectroscopy provide ongoing monitoring of impurities and product concentration. This overview optimises purification processes, reducing the need for excessive use of chromatography resins and buffers, cutting costs, and improving efficiency. By ensuring effective and efficient purification, continuous PAT maintains high product quality without unnecessary resource use.

• *Reduction of waste and rework*

Continuous PAT enables immediate detection of deviations, preventing the accumulation of out-of-specification products. This proactive approach minimises the need for reprocessing or discarding batches, leading to significant cost savings and reduced environmental impact. By maintaining product quality from the start, manufacturers avoid the inefficiencies and costs associated with waste and rework.

• *Integrated continuous manufacturing*

Continuous PAT supports seamless operation in manufacturing setups by providing ongoing feedback and control, crucial for uninterrupted processes. This integration helps maintain controlled-state conditions, ensuring high yield and consistent quality. Continuous PAT sustains optimal production conditions, enhancing overall process efficiency and product consistency.

• *Data-driven process optimisation*

The continuous data stream from PAT tools enables advanced analytics and machine learning applications. Manufacturers can use this data to identify trends, predict outcomes, and optimise downstream processes. This leads to more efficient operations and better resource utilisation. By leveraging data-driven insights, manufacturers can implement continuous improvement strategies and drive greater efficiency.

• *Improved regulatory compliance*

Continuous PAT supports compliance with stringent regulatory standards by providing thorough, real-time documentation of process conditions and product quality. This real-time monitoring aligns with modern regulatory requirements for continuous quality assurance and helps streamline regulatory audits and validations. Ensuring ongoing compliance, continuous PAT reduces the risk of regulatory issues and enhances product reliability.

• *Scalability and flexibility*

Continuous PAT systems can be scaled up or down to meet different production needs. This flexibility makes it easier to adapt to changes in production volume or product specifications without compromising on quality or efficiency. Whether expanding production capacity or adjusting to new product requirements, continuous PAT provides the adaptability needed to maintain high standards and efficiency.

Moving Forward with Continuous PAT

As the pharmaceutical industry continues to evolve, the adoption of continuous PAT will be essential for maintaining a competitive edge and meeting rising quality and efficiency demands. Integrating advanced analytical techniques and real-time data management will drive further innovation in downstream processing, ensuring that manufacturers can produce high-quality products both efficiently and cost-effectively. Embracing continuous PAT

will not only enhance current manufacturing capabilities but also pave the way for future advancements in pharmaceutical production.
Manufacturers can already benefit from continuous PAT solutions today, such as Optimal's synTQ platform. By integrating continuous PAT into downstream processes, companies can achieve higher efficiency, consistent product quality, and regulatory compliance. An investment in continuous PAT technology represents a strategic move towards a more agile, innovative, and competitive manufacturing operation.

1. https://www.europeanpharmaceuticalreview.com/article/217866/fractionation-purification-and-downstream-processing-the-path-to-commercialisation/

About Optimal Industrial Technologies Ltd
Within the Optimal group, we have more than 30 years' experience in the automation and optimisation of control and data management systems for the food, chemical, pharmaceutical, biotech, life science and other process industries.
The demands being placed on manufacturers in relation to getting products to market sooner, minimising development and production costs together with increasing product quality and business sustainability are ever increasing. Our primary aim is to deliver measurable improvements in all these target areas.
In addition to practical automation and system integration expertise, Optimal Industrial Technologies has also developed the world-leading PAT Knowledge Management software platform – synTQ® – which is used by over 60% of the world's leading pharmaceutical and biotech companies, and is now being adopted by other process industries. synTQ has been a proven enabler of QbD via PAT by significantly increasing productivity and quality, while reducing waste, time to manufacture and time to market for batch and continuous processes.

The image(s) distributed with this press release are for Editorial use only and are subject to copyright. The image(s) may only be used to accompany the press release mentioned here, no other use is permitted.